BridgeBio Pharma, Inc. has announced the pricing of $550 million in convertible senior notes due 2033. The notes will have an interest rate of 0.75% and a 45% conversion premium, with the company estimating net proceeds of approximately $538.4 million. The proceeds will be used for debt repayment and general corporate purposes. The notes will bear interest semi-annually, mature on February 1, 2033, and can be converted into cash or common stock. Holders have the right to require the company to repurchase the notes under certain events. The offering is expected to close on January 21, 2026.

Read more at GlobeNewswire: BridgeBio Prices Offering of $550 Million Convertible